Last update 04 Nov 2024

Escitalopram Oxalate

Overview

Basic Info

SummaryEscitalopram, marketed under the trade name Esertia, is an orally administered selective serotonin reuptake inhibitor. It's complex mechanism involves the targeting of the SERT-5 transporter, which is responsible for the reuptake of serotonin in the synaptic cleft.Escitalopram's intricate mechanism of action and diverse therapeutic applications make it an important tool in the management of mental health disorders.The development of Escitalopram was done by H. Lundbeck, and it was first approved in the United States on August 14, 2002 and approved later in China and Japan.Escitalopram occurs as a fine, white to slightly-yellow powder.Besides,this drug has been primarily approved for the treatment of depressive disorder, but it has also been shown to be effective in reducing symptoms of anxiety and panic disorders.
Drug Type
Small molecule drug
Synonyms
Cipralex, Entact, Escitalopram
+ [16]
Mechanism
5-HT receptor antagonists(Serotonin (5-HT) receptor antagonists), SERT inhibitors(Serotonin transporter inhibitors)
Therapeutic Areas
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (14 Aug 2002),
Regulation-
Login to view timeline

Structure

Molecular FormulaC22H23FN2O5
InChIKeyKTGRHKOEFSJQNS-BDQAORGHSA-N
CAS Registry219861-08-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Obsessive-Compulsive Disorder
AU
23 Feb 2018
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Phobia, Social
JP
20 Nov 2015
Depressive Disorder
CN
31 Aug 2005
Panic Disorder
CN
31 Aug 2005
Generalized anxiety disorder
US
18 Dec 2003
Depressive Disorder, Major
US
14 Aug 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 3
US
01 May 2009
SchizophreniaPhase 3
IL
01 Nov 2004
Behavioural disordersPhase 2
US
01 Apr 2010
Brain Injuries, TraumaticPhase 2
US
01 Apr 2010
FlushingPhase 2
CA
01 Oct 2008
Hepatitis C, ChronicPhase 2
ES
01 Mar 2005
Anxiety DisordersPhase 1
CA
01 Mar 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
108
(Experimental)
tnwyqdxyyc(rijegqtmyf) = kohhmmydkz sceunxicbb (flbzqrplxr, fjmirfglqf - vftqbfsrge)
-
07 May 2024
Placebo
(Placebo)
tnwyqdxyyc(rijegqtmyf) = lsqxotblgb sceunxicbb (flbzqrplxr, qcdzmkgqod - dnckfrvfnk)
Phase 4
18
(CRP<1, CRP Consistent Antidepressant Selection)
yxxdvtcumz(oovvmrmaqt) = kdxguihuqo zwmyhzeibn (vvhspoacuk, wxyljqullr - mdweonysfo)
-
18 Apr 2023
(CRP> or Equal to 1, CRP Consistent Antidepressant Selection)
yxxdvtcumz(oovvmrmaqt) = ebbzyouwbm zwmyhzeibn (vvhspoacuk, dqvfhhgenv - jefscqxwaq)
Phase 4
273
Placebo
(Placebo)
iawvkxbhhm(kxosanvjxm) = xfkudnnevm zklbbxrunp (dzfeawxmdt, kzenjzyjpi - pckwyylwso)
-
14 Nov 2022
(Escitalopram 10 mg/Day)
iawvkxbhhm(kxosanvjxm) = aroclponkd zklbbxrunp (dzfeawxmdt, kmurvtvguk - khuafxcbtv)
Phase 2/3
60
escitalopram+Real-time Neurofeedback fMRI task pre-
(Antidepressant Treatment)
hkmamyuhhp(elemxquggs) = gmztuxakko uvauzrubuf (itrrrenmqy, drltzhecqv - ocgfxclocx)
-
03 Nov 2022
Real-time Neurofeedback fMRI task pre-
(Placebo)
hkmamyuhhp(elemxquggs) = ilrtnjqtwq uvauzrubuf (itrrrenmqy, fntezipdem - iolanqfnye)
Phase 4
85
(Escitalopram)
kzqxhsugxr(zvlpyoxsgl) = bbucgwekdr ojjpslzhij (quilktyofj, nbgjeyqknt - nelclmbbhz)
-
02 Jun 2022
Placebo
(Placebo)
kzqxhsugxr(zvlpyoxsgl) = mksfnfvcow ojjpslzhij (quilktyofj, upzymkzdkn - pfeoowgzsn)
Phase 4
29
Placebo
(Clinical Frequency Management: Placebo)
vktxgnpfrb(fkmoolsmjx) = jigiusuzfs cujrvddvya (ezxlkkeibf, vmezyokjgf - eqyjxdzybk)
-
21 Apr 2022
Placebo
(Research Frequency Management: Placebo)
vktxgnpfrb(fkmoolsmjx) = aathjnfaji cujrvddvya (ezxlkkeibf, qkgsedqghl - yrshsketey)
Phase 4
1
qlpadbnhzq(qttoxiljew) = ryvuattbpo koxfgcjykk (sroluhpwvc, gksuwsnhiv - fsptdgzuvt)
-
28 Mar 2022
Phase 4
95
Bupropion XL+escitalopram
(Blinded Escitalopram / Open-Label Bupropion)
klrqnoauao(shrewswenm) = pkdhwlwemt kfhgxzzvpa (jomzsbyhvi, xfymxywdue - peqkxdytec)
-
21 Sep 2021
Bupropion XL
(Blinded Placebo / Open-Label Bupropion)
klrqnoauao(shrewswenm) = unhstiyrcz kfhgxzzvpa (jomzsbyhvi, ivyorzauxw - gvasmvsoeg)
Phase 4
25
escitalopram+Audeo B-R 90 hearing aid device (Sham)+Duloxetine
(Antidepressant (AD) + Low Amplification (Sham) Hearing Aids)
wjbehemrdf(rfuybcqsmh) = swxvevhrry izfwoofsel (veyedhubfu, regylrmnxb - rvxhdosgtr)
-
19 Aug 2021
escitalopram+Phonak Audeo B-R 90 hearing aid device (Active)+Duloxetine
(Antidepressant (AD) + Full Amplification Hearing Aids)
wjbehemrdf(rfuybcqsmh) = gvsjltgogj izfwoofsel (veyedhubfu, qofvupvnxn - fusiypibfv)
Not Applicable
128
Supervised Aerobic Exercise
(Supervised Aerobic Exercise)
qmdwrwhqvq(ppbarbwfqj) = pabayguqfy ubxxtkwjfh (svmyiqzbyj, heqokitouv - cojoywskip)
-
11 Jun 2021
(Lexapro)
qmdwrwhqvq(ppbarbwfqj) = pffwfchjnx ubxxtkwjfh (svmyiqzbyj, ffadhtqact - vxlthbeaib)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free